Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Einsatz neuer Substanzen in der Schwangerschaft
Translated title of the contribution
:
Targeted therapy for breast cancer during pregnancy
D. Fischer
*
, C. Dittmer, N. Bündgen, K. Diedrich, M. Thill, K. Röder
*
Corresponding author for this work
Clinic of Gynecology and Obstetrics
2
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeted therapy for breast cancer during pregnancy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Side Effect
50%
Trastuzumab
50%
Thalidomide
50%
Protein Tyrosine Kinase Inhibitor
25%
Lapatinib
25%
Receptor
25%
Medicine and Dentistry
Breast Cancer
100%
Side Effect
50%
Trastuzumab
50%
Tyrosine-Kinase Inhibitor
25%
Receptor
25%
Obstruction
25%
Bevacizumab
25%
Oligohydramnios
25%
Biochemistry, Genetics and Molecular Biology
Trastuzumab
100%
Tyrosine Kinase Inhibitor
50%
Lapatinib
50%
Bevacizumab
50%